Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 12/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6688756 | 0.82 | CNR1 (0.54) | ERN1MAPTSMN1; SMN2CDK1 | |
| SCHEMBL332380 | 0.82 | MAPT (0.62) | ERN1MAPTSMN1; SMN2CDK1 | |
| SCHEMBL209836 | 0.82 | ESR1 (0.55) | ERN1MAPTSMN1; SMN2CDK1 | |
| SCHEMBL11417093 | 0.80 | MAPT (0.61) | ERN1MAPTSMN1; SMN2CDK1 | |
| SCHEMBL16130218 | 0.80 | ERN1 (0.50) | ERN1MAPTSMN1; SMN2CDK1 | |
| SCHEMBL17079652 | 0.80 | ALDH1A1 (0.59) | MAPTSMN1; SMN2APP | |
| SCHEMBL30319438 | 0.80 | ALDH1A1 (0.59) | MAPTSMN1; SMN2APP | |
| SCHEMBL14849044 | 0.79 | ERN1 (0.49) | ERN1MAPTSMN1; SMN2CDK1 | |
| SCHEMBL16189491 | 0.78 | ESR1 (0.61) | APP | |
| SCHEMBL9291079 | 0.78 | ESR1 (0.52) | ERN1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242644-A1 | Factor Viia Inhibitor | PHARMACYCLICS, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| EP-1751114-A2 | FACTOR VIIA INHIBITOR | PHARMACYCLICS, INC. (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005121102-A2 | FACTOR VIIA INHIBITOR | PHARMACYCLICS, INC. (US) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242644-A1 | Factor Viia Inhibitor | F7, F9, F5 | ERN1 1540/4885MAPT 4562/4885SMN1; SMN2 4391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.